Herantis Pharma Plc announces Capital Markets Day webcast and provides update on business operations during COVID-19

Company will hold will hold a Capital Markets Day webcast on 24 March 2020 at 11:00 AM CET

Business operations including ongoing clinical trials and preparation for future studies continue as planned

Herantis Pharma Plc
Company release 24 Mar 2020 at 9:00 am

Herantis Pharma Plc
Press release 24 March 2020 at 9:00 AM Eastern European Time

 

Herantis Pharma Plc (“Herantis” or “Company”) announced today that a Capital Markets Day will be held through a webcast. In addition the Company provided  an update on its business operations during the COVID-19 (coronavirus) pandemic.

Herantis’ drug development pipeline currently has two active clinical programs: Lymfactin® is being tested in a Phase 2 clinical trial for the treatment of breast cancer associated lymphedema and CDNF is being tested in a Phase 1-2 clinical trial for the treatment of Parkinson’s disease. The studies are being conducted at university hospitals in Sweden and Finland.

Both of the clinical trials are fully recruited. All patient treatments have already been completed in the Lymfactin® trial, which has advanced to the 12-month blinded follow-up period. In the CDNF trial in Parkinson’s disease, all but four patients have completed their full 12-month active treatment period. The remaining treatments are planned to be completed by May 2020. While the COVID-19 outbreak may require the rescheduling of some of the planned treatments, the Company does not anticipate that such changes will have any material impact on the outcomes of these clinical trials.

The other ongoing activities of the Company include planning and preparations for a Phase 3 clinical study with Lymfactin® and a Phase 2 clinical study with CDNF, as well as lead optimization of the Company’s next generation, non-invasive asset, xCDNF, for the treatment of neurodegenerative diseases. These activities involve international subcontractors whose ability to provide services could be impacted by the present situation. As such, there may be delays in individual subprojects. However, the Company does not currently foresee essential impact on its plans, and the Company’s previously communicated Outlook for 2020 and Guidance for 2020 remain unchanged. Should changes to the guidance be needed in the future, the Company will announce these publicly.

“As the COVID-19 pandemic continues to evolve globally, we remain grateful that Herantis recently had the opportunity to establish a solid financial runway that will enable the Company to continue its daily business operations and advance its drug development pipeline including completing patient treatments,” commented Pekka Simula, Herantis’ CEO. “Moving forward, the health and safety of our employees remains of utmost concern and we have thereby cancelled all travel plans and will work from home offices. I am confident that by continuing to prioritize and adhere to safety guidelines as per organizations such as the World Health Organization, we will get through this pandemic.”

Herantis has cancelled several scheduled investor meetings and presentations due to the pandemic. Instead, the Company will hold a Capital Markets Day webcast on 24 March 2020 at 11:00 AM CET. In the webcast, the company’s CEO Pekka Simula, CSO Dr. Henri Huttunen and COO Dr. Antti Vuolanto will present an update on the Company’s activities. To participate in the webcast please register beforehand for “March 2020 Capital Markets Day Webcast of Herantis” on the website: https://www.gotostage.com/channel/herantis.

Questions can be submitted prior to the start of the webcast by e-mail to webcast@herantis.com. To the extent possible, the Company will also address questions submitted during the webcast. A recording of the webcast will be made available on the Company’s website.

 

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445

Company web site: www.herantis.com

 

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.